
ACADIA Pharmaceuticals Inc.: stock overview
Price
$18.75
November 13, 2026Market cap $3.2B
What Ploutos Investor adds for ACADIA Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.
In short
ACADIA Pharmaceuticals had revenue of $1.2B over the last 12 months and net income of $362M, a net margin of 30.1%. Revenue grew by 19.4% a year on average over the last 5 years. It holds more cash than debt, by $976M. It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.
Its SEC filings- Market cap
- $3.2B
- 170M shares
- P/E
- –
- Revenue, 12 months
- $1.2B
- +19.4% a year over 5 years
- Net margin
- 30.1%
- 2025: 36.5%, above 95% of its industry
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+21.5% a year over 2 years
Fiscal years in figures
ACAD's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $4.6B
- $3.2B
- Enterprise value
- $2.2B
- P/E
- –
- EV / EBIT
- 18.2
- EV / Revenue
- 1.9
- P/B 3-year median: 4.2
- 2.3
- FCF yield 3-year median: 2.3%
- 2.6%
- Earnings yield 3-year median: 7.4%
- –
Profitability
- Gross margin
- 90.5%
- Operating margin
- 10.2%
- Net margin 3-year median: 23.6%
- 30.1%
- ROIC
- 7.9%
- ROIC, 5-year average
- -10.2%
- ROE
- 29.8%
Growth
- Revenue, yearly change
- +11.9%
- EPS, yearly change
- –
- FCF, yearly change
- -33.1%
- Revenue, average a year
- +19.4%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $976M
- Total debt
- $72M
- Of which operating leases
- $72M
- Net cash
- $976M
- Net debt / EBITDA
- -7.9x
- Interest cover
- –
- Current ratio
- 3.82
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +2.2%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).
Operating margin
9.8%
Above 70% of the 285 companies in its industry, and 63% of all.
Net margin
36.5%
Above 95% of the 302 companies in its industry, and 95% of all.
ROE
31.9%
Above 89% of the 267 companies in its industry, and 92% of all.
ROA
25.0%
Above 94% of the 313 companies in its industry, and 98% of all.
Revenue growth
11.9%
Above 61% of the 292 companies in its industry, and 67% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- ACADIA PHARMACEUTICALS INC
- CIK
- 1070494
- Exchange
- NASDAQ
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 170M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with ACAD
- JNJJohnson & Johnson+0,00%Compare with ACAD
- ABBVAbbVie+0,00%Compare with ACAD
- UNHUnitedHealth+0,00%Compare with ACAD
- MRKMerck & Company+0,00%Compare with ACAD
- AMGNAmgen+0,00%Compare with ACAD
- TMOThermo Fisher Scientific+0,00%Compare with ACAD
- ABTAbbott Laboratories+0,00%Compare with ACAD
The full analysis
What do ACADIA Pharmaceuticals's filings show?
These are ACADIA Pharmaceuticals's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is ACAD's market cap?
ACADIA Pharmaceuticals Inc.'s market cap is $3.2B, at a price of $18.75 on November 13, 2026 and 170M shares.
How much revenue does ACAD have?
ACADIA Pharmaceuticals had revenue of $1.2B over the last 12 months. Over the last 5 years it changed by +19.4% a year on average.
Does ACAD pay a dividend?
No. ACADIA Pharmaceuticals paid no regular dividend over the last 12 months.
Where do the figures come from?
From ACADIA Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.